Description
Medical uses of CIMZIA (certolizumab pegol) injection
- Crohn’s Disease
On April 22, 2008, the U.S. Food and Drug Administration (FDA) approved Cimzia for the treatment of Crohn’s disease. - Rheumatoid arthritis
On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only/ - Psoriatic arthritis
On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis.
South Delhi Pharma Can Supply certolizumab pegol In India On Request –
certolizumab pegol, sold under the brand name CIMZIA®, is manufactured by UCB, Inc.. It has been approved by the FDA. For pricing information on CIMZIA® in India, please contact via phone or WhatsApp at +91-9891296838 or email at info@southdelhipharma.com. CIMZIA® is supplied in form: For injection. It can be made available in various cities across India, including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim.
NEWS / UPDATES
- FDA approves treatment for patients with a type of inflammatory arthritis For More Details
- FDA Approves Abrilada, Biosimilar to Humira, for Adults with Ankylosing Spondylitis and Other Disorders For More Details